Lonza has completed a planned expansion of its bioconjugation facility in Visp (CH). The expansion features two new manufacturing suites and supporting infrastructure that will enable Lonza to serve a wider customer base, including companies in clinical development. The investment increases Lonza's capabilities and flexibility to support both clinical and commercial supply and will be vital in meeting the rising market demand for bioconjugates. The new suites are a complement to Lonza's previous investments in Visp (CH) in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. By continuing to invest in Visp (CH), Lonza aims to provide a flexible solution for customers of all sizes, helping them navigate the risks of a complex bioconjugation supply chain. Additionally, the expansion includes an increase in process and analytical development and quality control capacity to support future portfolio growth.
According to Stefan Egli, Vice President and Head of Bioconjugates at Lonza, "The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Our bioconjugation services, combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, can support projects from early phase through to late-stage and commercial programs."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!